This inventor holds 1 USPTO granted patent. Top assignee: Innoplexus Ag. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Innovations of Manoj Kumar in Cancer Treatment
Introduction
Manoj Kumar is a notable inventor based in Bhagalpur, India. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on the treatment of pancreatic cancer, a disease that poses significant challenges in the medical community.
Latest Patents
Manoj Kumar holds a patent for "Phosphoinositide 3-kinase and Src inhibitors for treatment of pancreatic cancer." This patent describes a phosphoinositide 3-kinase inhibitor that is used in the treatment of pancreatic cancer. The method includes the administration of both a phosphoinositide 3-kinase inhibitor and an Src inhibitor to a human subject in need of treatment. Additionally, the patent provides a pharmaceutical composition that comprises both inhibitors, showcasing a novel approach to combat this aggressive form of cancer.
Career Highlights
Manoj Kumar is currently associated with Innoplexus AG, where he continues to advance his research in cancer therapies. His dedication to innovation in the pharmaceutical field has positioned him as a key figure in the development of effective treatments for pancreatic cancer.
Collaborations
Manoj collaborates with talented professionals such as Amit Choudhari and Deepak Sharma. Their combined expertise enhances the research and development efforts at Innoplexus AG, fostering an environment of innovation and discovery.
Conclusion
Manoj Kumar's contributions to cancer treatment through his patent on phosphoinositide 3-kinase and Src inhibitors highlight his commitment to improving patient outcomes. His work exemplifies the impact of innovative research in the medical field, particularly in the fight against pancreatic cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
